Quest Partners LLC Sells 4,780 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Quest Partners LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 78.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,276 shares of the company’s stock after selling 4,780 shares during the period. Quest Partners LLC’s holdings in Viridian Therapeutics were worth $29,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Viridian Therapeutics by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after buying an additional 233,331 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Viridian Therapeutics by 20.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,369 shares of the company’s stock worth $550,000 after acquiring an additional 5,429 shares in the last quarter. California State Teachers Retirement System increased its position in Viridian Therapeutics by 13.9% during the 1st quarter. California State Teachers Retirement System now owns 42,596 shares of the company’s stock valued at $746,000 after purchasing an additional 5,202 shares during the period. SG Americas Securities LLC purchased a new stake in Viridian Therapeutics during the second quarter worth $599,000. Finally, Hennion & Walsh Asset Management Inc. boosted its position in Viridian Therapeutics by 62.9% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 178,855 shares of the company’s stock valued at $2,327,000 after acquiring an additional 69,035 shares in the last quarter.

Viridian Therapeutics Trading Down 1.5 %

Shares of NASDAQ:VRDN opened at $21.55 on Monday. The business’s 50 day moving average price is $22.72 and its 200-day moving average price is $17.43. Viridian Therapeutics, Inc. has a 1 year low of $11.40 and a 1 year high of $27.20. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -5.00 and a beta of 1.10. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. On average, equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of Viridian Therapeutics stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the acquisition, the director now owns 3,445,813 shares in the company, valued at approximately $64,608,993.75. This represents a 86.68 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Thomas W. Beetham bought 5,000 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the transaction, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at $140,460. The trade was a 500.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 1,626,400 shares of company stock valued at $30,616,312 in the last three months. 0.65% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

VRDN has been the subject of a number of recent research reports. HC Wainwright boosted their target price on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. The Goldman Sachs Group raised their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. TD Cowen assumed coverage on Viridian Therapeutics in a research note on Monday, November 25th. They set a “buy” rating on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Thursday, September 19th. Finally, BTIG Research raised their target price on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.33.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.